Kalın Gamze, Metan Gökhan, Demiraslan Hayati, Doganay Mehmet
J Chemother. 2014 Jun;26(3):146-9. doi: 10.1179/1973947813Y.0000000123. Epub 2013 Dec 6.
The role of ribavirin in the treatment of Crimean-Congo hemorrhagic fever (CCHF) is scarce. We retrospectively reviewed treatment features of 81 hospitalized patients with laboratory confirmed CCHF between January 2007 and December 2010. The median age of the patients was 45 years and 47 were male. Out of 81 patients, 6 received ribavirin. Demographic characteristics and laboratory findings of the patients who received ribavirin were not different from the patients who did not receive antiviral. There were no statistically significant difference in duration of symptoms before admission (P = 0·47) between the two groups. Of the patients, 29 who did not receive ribavirin and four from the ribavirin treated group had severe disease based on the Swanpoel criteria (P = 0·22). Two patients from each group died. There was no statistically significant difference in case fatality (P = 0·14) and duration of hospitalization (P = 0·11). Treatment of CCHF without ribavirin seems to be safe based on the findings of this study.
利巴韦林在克里米亚-刚果出血热（CCHF）治疗中的作用尚少。我们回顾性分析了2007年1月至2010年12月期间81例实验室确诊为CCHF的住院患者的治疗特征。患者的中位年龄为45岁，其中47例为男性。81例患者中，6例接受了利巴韦林治疗。接受利巴韦林治疗的患者的人口统计学特征和实验室检查结果与未接受抗病毒治疗的患者并无差异。两组患者入院前症状持续时间无统计学显著差异（P = 0.47）。根据斯旺普尔标准，未接受利巴韦林治疗的29例患者和利巴韦林治疗组的4例患者病情严重（P = 0.22）。每组各有2例患者死亡。病死率（P = 0.14）和住院时间（P = 0.11）无统计学显著差异。基于本研究结果，不使用利巴韦林治疗CCHF似乎是安全的。
